In the News
In the News
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1) is now open in the US and Europe and is actively recruiting patients.
The study is seeking 200 patients at over 50 institutions in a randomized trial - those that are randomized to the non-PRRT arm will receive LAR 60 (high dose).
To learn more about the trial, please visit clinicaltrials.gov.
While we were in Chandigarh, India for the 2nd World Congress on Ga68 we were abole to film the following press conference with Professors Baum, Shultz and Singh about the importance of the Congress. Please make sure to click the read more button to see all 3 talks.
Patient knowledge and understanding of radiation from diagnostic imaging is lacking, according to a research letter published online Dec. 31, 2012, in JAMA Internal Medicine . More than half of patients surveyed heard nothing in the media about radiation from medical imaging, and many of those aware of radiation exposure substantially underestimated dose.
Read more at healthimaging.com
We at PRRTinfo.org are working with the Society of Nuclear Medicine and Molecular Imaging to provide
A method of molecular imaging that pinpoints hormonally active tissues in the body could change the course of treatment for a remarkable number of neuroendocrine cancer patients, say researchers at the Society of Nuclear Medicine's 59th Annual Meeting.
Results of the study indicated that PET/CT and Ga-68 DOTATATE was highly sensitive and specific for assessing neuroendocrine tumors and changed thecourse of treatment for a large number of patients. Prior to imaging, more than half of the